Teva announces acquisition of Corporación Infarmasa

Teva Pharmaceutical Industries Ltd. announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments.

Infarmasa manufactures and commercializes branded and unbranded generic drugs, primarily corticosteroids, antihistamines, analgesics and antibiotics. Its portfolio consists of over 600 registered products, of which over 500 are currently marketed. Infarmasa's product offerings will greatly enhance Teva's portfolio in the market, especially in the area of antibiotics, where Infarmasa has the leading brand in Perú. The company also has two manufacturing facilities in Lima and a comprehensive development pipeline. The combination of Corporación Medco (Teva's existing operation in Perú) and Infarmasa will be one of the top two pharmaceutical companies in the country.

Commenting on today's transaction, Shlomo Yanai, Teva's President and Chief Executive Officer, stated, "The acquisition of Infarmasa in Perú expands our activity in Latin America, and highlights our growth strategy for the coming years. Infarmasa complements Teva's activity in Perú and will advance our position as a market leader in this region."

The Peruvian pharmaceutical market grew at a CAGR of 12% from 2005 to 2010 and is expected to reach $1.8 billion in 2015. Expenditure per capita on pharmaceuticals in Perú is one of the lowest in Latin America, providing significant opportunities for future growth. Healthcare coverage has also increased substantially over the past five years, from approximately 36% of the population in 2005 to 63% by the end of 2009.